MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

详细信息    查看全文

• 作者：Roberta Biundo ; L. Weis ; S. Bostantjopoulou ; E. Stefanova…
• 关键词：Parkinson disease ; MMSE ; MoCA ; Dementia with Lewy bodies ; Rate of cognitive decline
• 刊名：Journal of Neural Transmission
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：123
• 期：4
• 页码：431-438
• 全文大小：842 KB
• 参考文献：Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P (2004) The rate of cognitive decline in Parkinson disease. Arch Neurol 61:1906–1911CrossRef PubMed
  Aarsland D, Beyer MK, Kurz MW (2008) Dementia in Parkinson’s disease. Curr Opin Neurol 21:676–682CrossRef PubMed
  Aarsland D, Muniz G, Matthews F (2011a) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26:334–337CrossRef PubMed
  Aarsland D, Muniz G, Matthews F (2011b) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26:334–337CrossRef PubMed
  Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, Antonini A (2014) Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord 20:394–399CrossRef PubMed
  Bland JM, Altman DG (1995) Comparing two methods of clinical measurement: a personal history. Int J Epidemiol 24(Suppl 1):S7–S14CrossRef PubMed
  Breitve MH, Chwiszczuk LJ, Hynninen MJ, Rongve A, Bronnick K, Janvin C, Aarsland D (2014) A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease. Alzheimers Res Ther 6:53-014-0053-6 (eCollection 2014)
  Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Troster AI, Uc EY, Parkinson Study Group Cognitive/Psychiatric Working Group (2010) A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord 25:2501–2507CrossRef PubMed PubMedCentral
  Chou KL, Lenhart A, Koeppe RA, Bohnen NI (2014) Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord 20:1076–1080CrossRef PubMed PubMedCentral
  Cohen J (1988) Statistical power analysis for the behavioral sciences. L. Erlbaum Associates, Hillsdale
  Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord 26:629–636CrossRef PubMed
  Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRef PubMed
  Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRef PubMed
  Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39CrossRef PubMed
  Gill DJ, Freshman A, Blender JA, Ravina B (2008) The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease. Mov Disord 23:1043–1046CrossRef PubMed
  Glatt SL, Hubble JP, Lyons K, Paolo A, Troster AI, Hassanein RE, Koller WC (1996) Risk factors for dementia in Parkinson’s disease: effect of education. Neuroepidemiology 15:20–25CrossRef PubMed
  Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745CrossRef PubMed PubMedCentral
  Hu MT, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29:351–359CrossRef PubMed PubMedCentral
  Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602CrossRef PubMed
  Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC (2014) Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 20:1145–1148CrossRef PubMed
  Kelley K (2007) Sample size planning for the coefficient of variation from the accuracy in parameter estimation approach. Behav Res Methods 39:755–766CrossRef PubMed
  Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–1408PubMed
  Lessig S, Nie D, Xu R, Corey-Bloom J (2012a) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128CrossRef PubMed
  Lessig S, Nie D, Xu R, Corey-Bloom J (2012b) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128CrossRef PubMed
  Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51:722–729CrossRef PubMed
  Malek-Ahmadi M, Powell JJ, Belden CM, O’Connor K, Evans L, Coon DW, Nieri W (2015) Age- and education-adjusted normative data for the Montreal Cognitive Assessment (MoCA) in older adults age 70–99. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 22:755–761CrossRef PubMed
  McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872CrossRef PubMed
  Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRef PubMed
  Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257:359–366CrossRef PubMed PubMedCentral
  Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C (2014) Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer’s disease and Lewy body dementia. Dement Geriatr Cogn Disord 38:161–169CrossRef PubMed
  Owen AM (2004) Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist 10:525–537CrossRef PubMed
  Richardson JTE (2011) The analysis of 2 × 2 contingency tables—Yet again. Stat Med 30:890CrossRef PubMed
  Rongve A, Vossius C, Nore S, Testad I, Aarsland D (2014) Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia. Int J Geriatr Psychiatry 29:392–398CrossRef PubMed
  Santangelo G, Siciliano M, Pedone R, Vitale C, Falco F, Bisogno R, Siano P, Barone P, Grossi D, Santangelo F, Trojano L (2015) Normative data for the Montreal Cognitive Assessment in an Italian population sample. Neurol Sci 36:585–591CrossRef PubMed
  Temlett JA, Thompson PD (2006) Reasons for admission to hospital for Parkinson’s disease. Intern Med J 36:524–526CrossRef PubMed
  Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRef PubMed
  van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, Chahine LM, Dahodwala N, Trojanowski JQ, Roalf DR, Moberg PJ, Weintraub D (2014) Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson’s disease. Mov Disord 29:1809–1815CrossRef PubMed PubMedCentral
  Verghese J, Crystal HA, Dickson DW, Lipton RB (1999) Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 53:1974–1982CrossRef PubMed
  Wang CS, Pai MC, Chen PL, Hou NT, Chien PF, Huang YC (2013) Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer’s disease, and normal participants in Taiwan. Int Psychogeriatr 25:1839–1848CrossRef PubMed
  Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS, Tan L (2015) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 86:135–143CrossRef PubMed
  Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C (2008) A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord 23:297–299CrossRef PubMed
  
• 作者单位：Roberta Biundo (1)
  L. Weis (1)
  S. Bostantjopoulou (2)
  E. Stefanova (3)
  C. Falup-Pecurariu (4)
  M. G. Kramberger (5)
  G. J. Geurtsen (6)
  A. Antonini (1)
  D. Weintraub (7)
  D. Aarsland (8) (9)
  
  1. Parkinson’s Disease and Movement Disorders Unit, “Fondazione Ospedale San Camillo” - I.R.C.C.S., Via Alberoni 70, 30126, Venice-Lido, Italy
  2. 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloníki, Greece
  3. Clinic of Neurology CCS, School of Medicine, University of Belgrade, Belgrade, Serbia
  4. Department of Neurology, Faculty of Medicine, County Emergency Clinic Hospital, Transilvania University, Brasov, Romania
  5. Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia
  6. Department of Medical Psychology, Academic Medical Hospital, Amsterdam, The Netherlands
  7. Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
  8. Department of NVS, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden
  9. Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Pharmacology and Toxicology
  Psychiatry
  
• 出版者：Springer Wien
• ISSN：1435-1463

文摘

The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects.